China SXT Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1.14	1.74	1.93	1.97	2.6
Revenue Growth (YoY)	-34.63%	-9.73%	-2.19%	-24.23%	-45.53%
Cost of Revenue	0.89	1.37	1.37	1.55	1.35
Gross Profit	0.25	0.37	0.55	0.43	1.25
Selling, General & Admin	7.37	3.05	3.07	6.03	6.44
Total Operating Expenses	7.37	3.05	3.07	6.03	6.44
Operating Income	-7.12	-2.68	-2.52	-5.61	-5.19
Total Non-Operating Income (Expense)	0.92	-0.62	-0.58	-0.33	-0.22
Pretax Income	-6.21	-3.3	-3.1	-5.93	-5.41
Provision for Income Taxes	-	-	-	-	-0.33
Net Income	-6.21	-3.3	-3.1	-5.93	-5.08
Net Income to Common	-6.21	-3.3	-3.1	-5.93	-5.74
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change (YoY)	7062.48%	1212.45%	224.97%	541.91%	44.50%
EPS (Basic)	-9.13	-348.17	-4285.66	-26675.50	-165502.00
EPS (Diluted)	-9.13	-348.17	-4285.66	-26675.50	-165502.00
Free Cash Flow	-4.02	-2.35	-1.94	-0.15	0.21
Free Cash Flow Per Share	-5.91	-247.38	-2676.51	-680.70	5937.91
Gross Margin	21.85%	21.11%	28.73%	21.62%	48.10%
Operating Margin	-625.89%	-153.97%	-130.42%	-284.40%	-199.43%
Profit Margin	-545.24%	-189.77%	-160.67%	-301.00%	-195.21%
FCF Margin	-353.01%	-134.83%	-100.34%	-7.68%	7.91%
EBITDA	-6.98	-2.53	-2.24	-5.36	-4.87
EBITDA Margin	-613.30%	-145.26%	-116.26%	-271.72%	-187.13%
EBIT	-7.12	-2.68	-2.52	-5.61	-5.19
EBIT Margin	-625.89%	-153.97%	-130.42%	-284.40%	-199.43%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	6.07%

SEC Filings: 10-K · 10-Q